Ec 5000 excimer laser

A standardized examination protocol was followed in all patients. Patients were examined preoperatively, 1-day, 1-week, 1-month, and at 6 months postoperatively. Preoperative and 6 months postoperative data are reported here. Preoperative and 6 month postoperative examinations included measurement of uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA) (projector chart [feet system], Nidek Co. Ltd., Gamagori, Japan), noncycloplegic and cycloplegic refraction (ARK-700 auto-refracto-keratometer, Nidek Co. Ltd., Gamagori, Japan), and subjective refractions with a trial lens set. Subjective patient satisfaction and evaluation of the visual outcome postoperatively were assessed by patients completing a survey questionnaire at 6 months postoperatively. The NIDEK EC-5000 excimer laser (NIDEK Co. Ltd., Gamagori, Japan) was used for all treatments. The Moria M2 microkeratome (Moria Co., Antony, France) was used to create a superiorly hinged flap with a 90 mm depth plate producing flap thickness of 90-120 mm. The NIDEK US 1000 pachymeter (NIDEK Co. Ltd., Gamagori, Japan) was used to measure flap thickness.

Rabbits premedicated with intramuscular (IM) injection of midazolam (0.7 mg/kg) and hydromorphone (0.1 mg/kg) were anesthetized using an IM injection of ketamine (15–30 mg/kg) followed by isoflurane (1%–4%) inhalation. The surgical area was disinfected with 0.2% povidone-iodine solution. The cornea of the right eye (OD) was treated with 0.5% proparacaine hydrochloride ophthalmic solution (Alcon) and a central zone marked with an 8 mm trephine (MSI Instruments, Phoenixville, PA). The epithelium within the marked area was then debrided using an excimer spatula (Beaver-Visitec International, Inc, Waltham, MA) followed by a PTK (6 mm diameter, 40 Hz, 250 pulses, 100 µm depth) using a NIDEK EC-5000 excimer laser (Nidek Co. Ltd, Gamagori, Japan) as described previously.³⁸ (link) The left eye remained unwounded and served as a control. Atropine sulfate ophthalmic solution 1% (Akorn, Inc., Lake Forest, IL) and ofloxacin 0.3% ophthalmic solution (Alcon) were administrated OD following the PTK treatment. Buprenorphine (0.04 mg/kg) was administered subcutaneously for postoperative analgesia. Rabbits were randomly assigned to receive 40 µl of BSS (n = 6, vehicle control) or Fe₂O₃ NP (250 µg/ml) in BSS (n = 6) in both eyes six times a day.